

# Pipeline

## Efgartigimod alfa (IV) Efgartigimod alfa and hyaluronidase- qvcf (SC)

Target:  
FcRn

Clinical trial    Preclinical    Phase 1    Proof of Concept    Registrational



AChR- Generalized Myasthenia Gravis (gMG)(IV)



Thyroid Eye Disease (TED)(SC)



Bullous Pemphigoid (BP)(SC)



Myositis (IMNM, ASyS, DM)(SC)



Sjogren's Disease (IV)



IQVIA



Membranous Nephropathy (MN)(IV)



zai-lab



Lupus Nephropathy (LN)(IV)



zai-lab



Antibody Mediated Rejection (AMR)



## Empasiprubart

Target:  
C2



Multifocal Motor Neuropathy (MMN)



Delayed Graft Function (DGF)



Dermatomyositis (DM)



## ARGX-119

Target:  
MuSK

Congenital Myasthenic Syndrome (CMS)



Amyotrophic Lateral Sclerosis (ALS)



Neurology    Hematology/Rheumatology    Nephrology    Dermatology

